Clinical trial
A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)
NCT03055806 is registered in ClinicalTrials.gov with Ixchelsis Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)
- Lead sponsor
- Ixchelsis Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2017
- Completion date
- December 6, 2017
- Enrollment
- 239 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.